Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05338658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of PAT in Patients With Solid Tumor Cancers

StatusRecruiting
PhasePhase 1
Started2023-05-19
View on ClinicalTrials.gov ↗

Amendment history

2025-12-08
Suspended→Recruiting Study Status, Contacts/Locations v5
Trial statusSuspended→Recruiting
Reason stoppedPending final IP→not stated
Study sitesdetails revised at 1 of 1 site
2025-07-29
2 amendments v3-v4
2 re-verifications since 2024-07-24, no change to tracked fields
2023-07-20
Not Yet Recruiting→Suspended Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Suspended
Reason stoppednot stated→Pending final IP
Start dateestimated 2023-04-30→confirmed 2023-05-19
Study sites0→1
2022-11-02
Study Status v1
Start date2022-05→2023-04-30
2022-04-14
Original filing
This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor
Trial Details
NCT Number NCT05338658
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Metastasis, Solid Tumor
Enrollment 21 participants
Start Date 2023-05-19
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-09